You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 8,900,566


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,900,566 protect, and when does it expire?

Patent 8,900,566 protects DAKLINZA and is included in one NDA.

This patent has sixty-eight patent family members in thirty-one countries.

Summary for Patent: 8,900,566
Title:Hepatitis C virus inhibitors
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Inventor(s): Belema; Makonen (North Haven, CT), Nguyen; Van N. (Middletown, CT)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:14/030,199
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,900,566

Introduction

United States Patent 8,900,566, titled "Hepatitis C virus inhibitors," is a significant patent in the field of pharmaceuticals, particularly for the treatment of Hepatitis C virus (HCV) infection. This patent, along with others in the same family, plays a crucial role in the intellectual property landscape of HCV treatments.

Patent Overview

The patent in question, US8900566B2, is part of a series of patents related to compounds, compositions, and methods for treating HCV infection. Here is a breakdown of its key components:

Inventors and Assignees

This patent is assigned to Bristol-Myers Squibb Company, a major pharmaceutical firm. The inventors listed are researchers who have contributed to the development of the compounds and methods described in the patent.

Publication and Filing Dates

The patent was published on December 2, 2014, and is a continuation of earlier patent applications, highlighting the evolutionary nature of patent filings in complex technological fields[4].

Claims Analysis

The claims section of a patent is critical as it defines the scope of protection granted to the inventor.

Independent and Dependent Claims

The patent includes both independent and dependent claims. Independent claims stand alone and define the invention broadly, while dependent claims build upon the independent claims and provide additional specificity. For example, Claim 1 of US8900566B2 describes a general structural formula of the base compound, including various substituents, which is a broad independent claim. Dependent claims, such as Claim 2, further specify the substituents and their configurations[4].

Strategic Claim Management

The management of claims in this patent is strategic and aligns with best practices in patent law. The inclusion of multiple dependent claims ensures comprehensive protection of the invention. This approach maximizes the patent’s breadth and flexibility, as each claim can be viewed as a unique tool for protecting different facets of the invention[5].

Patent Scope

The scope of the patent is defined by its claims and the descriptions provided in the specification.

Primary and Secondary Patents

US8900566B2 is considered a primary patent as it discloses the base compound and its general structural formula. Secondary patents related to this invention might cover specific pharmaceutical formulations, methods of use, product derivatives, and processes. These secondary patents can be easier to circumvent, but they still play a crucial role in delaying the entry of generic medicines[1].

Novelty and Inventive Step

The patent application underwent a World Intellectual Property Organization (WIPO) International Search Report (ISR), which indicated that the invention was novel and not obvious compared to the closest prior art. This validation is crucial for the patent's enforceability and highlights the innovative nature of the compounds described[1].

Patent Landscape Analysis

Understanding the broader patent landscape is essential for navigating technological domains and making informed business decisions.

Patent Mapping

Patent landscape analysis, or patent mapping, involves analyzing and organizing vast amounts of patent data to extract valuable insights. This includes identifying pending or granted patents in the same field, their legal status, expected expiry dates, and geographical coverage. For US8900566B2, this analysis would reveal its position within the HCV treatment patent landscape, including competitors and potential licensing opportunities[3].

Competitor Analysis

The patent landscape analysis helps in identifying key competitors and their patent portfolios. For instance, other pharmaceutical companies may have similar patents or be developing competing treatments. This information is vital for strategic planning, including potential collaborations, licensing agreements, or litigation strategies[3].

Market Developments

The analysis also reveals market trends such as mergers and acquisitions, in/out-licensing agreements, and litigation activities. These insights are critical for minimizing business risks and capitalizing on opportunities. For example, the sub-license agreement for daclatasvir, a related compound, covers several patents and allows for the sale of generic versions in low- and middle-income countries[1].

Legal Status and Expiry Dates

The legal status of a patent, including its expected expiry dates, is crucial for planning future strategies.

Current Status

As of the current date, the legal status of US8900566B2 would need to be verified through the USPTO or other reliable sources. Patents typically expire 20 years from the earliest filing date of the application, but this can be affected by various factors such as maintenance fees and any adjustments during the prosecution phase[4].

Impact of Expiry

The expiry of this patent would open up the market for generic versions of the HCV inhibitors, potentially reducing costs and increasing accessibility of the treatment. However, secondary patents related to formulations, methods of use, or other aspects might still be in force, delaying full generic entry[1].

Strategic Implications

Licensing and Collaboration

The patent's scope and claims can be leveraged in licensing agreements or collaborations. Ensuring that the patent utilizes its full complement of claims enhances its value in such discussions, providing a robust and nuanced protection that can be attractive to potential partners[5].

Infringement and Litigation

The strategic management of claims also strengthens the patent's defensive capabilities in infringement disputes. Each claim acts as a unique tool for protecting different facets of the invention, making it more difficult for competitors to infringe without violating at least one claim[5].

Key Takeaways

  • Comprehensive Claims: The patent includes a mix of independent and dependent claims to ensure broad and specific protection.
  • Strategic Management: The management of claims is crucial for maximizing the patent’s value and defensive capabilities.
  • Patent Landscape: Understanding the broader patent landscape helps in identifying competitors, market trends, and potential opportunities.
  • Legal Status and Expiry: Keeping track of the patent’s legal status and expected expiry dates is vital for strategic planning.
  • Licensing and Litigation: The patent’s scope and claims are key in licensing agreements and infringement disputes.

FAQs

  1. What is the main subject of United States Patent 8,900,566?

    • The main subject is compounds, compositions, and methods for the treatment of Hepatitis C virus (HCV) infection.
  2. What is the significance of primary and secondary patents in this context?

    • Primary patents disclose the base compound, while secondary patents cover specific formulations, methods of use, and other aspects, which can delay generic entry.
  3. How does patent landscape analysis help in understanding this patent?

    • It provides insights into competitors, market trends, legal status, and expected expiry dates, aiding in strategic decision-making.
  4. What is the importance of claim management in patent filings?

    • Strategic claim management ensures comprehensive protection, maximizes the patent’s value, and enhances its defensive capabilities.
  5. What happens when a patent like US8900566B2 expires?

    • The expiry opens up the market for generic versions, but secondary patents might still delay full generic entry.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,900,566

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-001 Jul 24, 2015 DISCN Yes No ⤷  Subscribe ⤷  Subscribe METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY ⤷  Subscribe
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-001 Jul 24, 2015 DISCN Yes No ⤷  Subscribe ⤷  Subscribe METHOD OF INHIBITING HEPATITIS C VIRUS ⤷  Subscribe
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-002 Jul 24, 2015 DISCN Yes No ⤷  Subscribe ⤷  Subscribe METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY ⤷  Subscribe
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-002 Jul 24, 2015 DISCN Yes No ⤷  Subscribe ⤷  Subscribe METHOD OF INHIBITING HEPATITIS C VIRUS ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,900,566

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2049522 ⤷  Subscribe C300713 Netherlands ⤷  Subscribe
European Patent Office 2049522 ⤷  Subscribe CA 2015 00003 Denmark ⤷  Subscribe
European Patent Office 2049522 ⤷  Subscribe C20150003 00128 Estonia ⤷  Subscribe
European Patent Office 2049522 ⤷  Subscribe PA2015006 Lithuania ⤷  Subscribe
European Patent Office 2049522 ⤷  Subscribe 92635 Luxembourg ⤷  Subscribe
European Patent Office 2049522 ⤷  Subscribe 15C0007 France ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.